Novartis, a Swiss multinational pharmaceutical company, agreed to acquire Calypso Biotech, a biotechnology company that develops treatment for patients suffering from severe gastro-intestinal diseases, for $425m. “We are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications,” Alain Vicari, Calypso CEO & Co-Founder.